Biomarkers Market Analysis 2025–2029: Growth Forecast and Competitive Insights

Uncover key drivers, emerging technologies, and competitive movements shaping the biomarkers market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Biomarkers Market Be Worth By 2029, And What CAGR Will It Achieve?

The biomarkers market has seen rapid expansion in recent years. Its value is projected to increase from $68.77 billion in 2024 to $77.42 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.6%. This historical growth is attributable to advancements in genomics and proteomics technologies, the rising prevalence of chronic diseases, a heightened focus on personalized medicine, the escalating demand for companion diagnostics, and the broadening scope of applications in drug development.

The biomarkers market is projected to experience substantial growth in the upcoming years, with its size expected to reach $131.78 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 14.2%. This anticipated expansion during the forecast period stems from factors such as an intensified focus on early disease identification and prevention, the broader application of biomarkers in oncology and immunotherapy, increasing financial commitment to precision medicine initiatives, the proliferation of liquid biopsy as a non-invasive method for biomarker detection, and the rising utilization of biomarkers in drug discovery and development. Noteworthy trends predicted for this period include the creation of multi-biomarker panels, the emergence of exosome-based biomarkers, the implementation of point-of-care biomarker testing, the integration of real-world data into biomarker research, and the exploration of microbiome-derived biomarkers.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

Which Factors Are Driving The Biomarkers Market Forward?

The surge in heart diseases is anticipated to significantly fuel the expansion of the biomarkers market throughout the projected timeframe. The application of biomarkers in patients suffering from heart disease has seen a substantial rise in recent years. At present, natriuretic peptides are the most frequently utilized biomarkers, aiding in the diagnosis of individuals with heart failure. Furthermore, circulating biomarkers, such as high sensitivity C-reactive protein, are also employed for diagnosing heart failure. Given that heart disease ranks among the primary causes of death for most racial and ethnic groups within the United States, an escalation in its prevalence will consequently boost the demand for biomarkers. For example, in August 2022, a report from the American College of Cardiology, a US-based non-profit medical association, indicated a projected increase in all four cardiovascular risk factors in the United States between 2025 and 2060. The most substantial percentage growth is predicted for diabetes, rising by 39.3% to 55 million individuals, followed by dyslipidemia, which is expected to increase by 27.6% to 126 million, hypertension by 25.1% to 162 million, and obesity by 18.3% to 126 million. Researchers also noted that the largest projected increases in cardiovascular disease rates were observed for stroke, at 33.8% to 15 million, and heart failure, at 33.4% to 13 million, with ischemic heart disease increasing by 30.7% to 29 million, and heart attack by 16.9% to 16 million. This overall increase in heart diseases and related deaths is expected to contribute to a rise in growth for biomarkers.

Which Segments Form The Key Structure Of The Biomarkers Market?

The biomarkers market covered in this report is segmented –

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases

3) By Type: Biomarker Of Exposure, Biomarker Of Diseases

4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers

2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers

3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

What Strategic Shifts And Innovations Are Influencing The Biomarkers Market?

Leading companies active in the biomarker market are concentrating on developing innovative solutions, such as a new biological marker, to boost innovation through collaborative research, technology integration, and strong clinical validation. A novel biological marker is a recently identified indicator that reflects biological processes and helps in diagnosing or tracking diseases. It can manifest as a molecule, gene, or cellular characteristic with potential significance for personalized medicine. For instance, in September 2024, Genialis, a US-based computational precision medicine company, introduced a first-in-class biomarker. This biomarker significantly improves the predictive accuracy for patient responses to KRAS inhibitors, allowing for personalized treatment plans and enhanced clinical outcomes. Its extensive use across various cancer types facilitates efficient drug development and optimizes patient selection for targeted therapies.

Which Firms Are Making The Biggest Impact In The Biomarkers Market?

Major companies operating in the biomarkers market include Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Which Region Is Expected To Lead The Biomarkers Market In The Next Few Years?

North America was the largest region in the biomarkers market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

Browse Through More Reports Similar to the Global Biomarkers Market 2025, By The Business Research Company

Small Animal Imaging In Vivo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/small-animal-imaging-in-vivo-global-market-report

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Biologics Market 2025

https://www.thebusinessresearchcompany.com/report/biologics-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795